148 related articles for article (PubMed ID: 28542311)
1. 18F-FDG PET/CT-based early treatment response evaluation of nanoparticle-assisted photothermal cancer therapy.
Norregaard K; Jørgensen JT; Simón M; Melander F; Kristensen LK; Bendix PM; Andresen TL; Oddershede LB; Kjaer A
PLoS One; 2017; 12(5):e0177997. PubMed ID: 28542311
[TBL] [Abstract][Full Text] [Related]
2.
Simón M; Jørgensen JT; Norregaard K; Kjaer A
Sci Rep; 2020 May; 10(1):7595. PubMed ID: 32371864
[TBL] [Abstract][Full Text] [Related]
3. Dynamic 2-Deoxy-2-[
Kristian A; Holtedahl JE; Torheim T; Futsaether C; Hernes E; Engebraaten O; Mælandsmo GM; Malinen E
Mol Imaging Biol; 2017 Apr; 19(2):271-279. PubMed ID: 27541026
[TBL] [Abstract][Full Text] [Related]
4. Comparison of Positron Emission Tomography Using 2-[18F]-fluoro-2-deoxy-D-glucose and 3-deoxy-3-[18F]-fluorothymidine in Lung Cancer Imaging.
Wang FL; Tan YY; Gu XM; Li TR; Lu GM; Liu G; Huo TL
Chin Med J (Engl); 2016 Dec; 129(24):2926-2935. PubMed ID: 27958224
[TBL] [Abstract][Full Text] [Related]
5. Experimental study on the therapeutic effect of positron emission tomography agent [¹⁸F]-labeled 2-deoxy-2-fluoro-d-glucose in a colon cancer mouse model.
Fang S; Wang J; Jiang H; Zhang Y; Xi W; Zhao C; Tian M; Zhang H
Cancer Biother Radiopharm; 2010 Dec; 25(6):733-40. PubMed ID: 21204768
[TBL] [Abstract][Full Text] [Related]
6. Preclinical and clinical evidence that Deoxy-2-[18F]fluoro-D-glucose positron emission tomography with computed tomography is a reliable tool for the detection of early molecular responses to erlotinib in head and neck cancer.
Vergez S; Delord JP; Thomas F; Rochaix P; Caselles O; Filleron T; Brillouet S; Canal P; Courbon F; Allal BC
Clin Cancer Res; 2010 Sep; 16(17):4434-45. PubMed ID: 20660574
[TBL] [Abstract][Full Text] [Related]
7. Single Particle and PET-based Platform for Identifying Optimal Plasmonic Nano-Heaters for Photothermal Cancer Therapy.
Jørgensen JT; Norregaard K; Tian P; Bendix PM; Kjaer A; Oddershede LB
Sci Rep; 2016 Aug; 6():30076. PubMed ID: 27481537
[TBL] [Abstract][Full Text] [Related]
8. A thermo-responsive alginate nanogel platform co-loaded with gold nanoparticles and cisplatin for combined cancer chemo-photothermal therapy.
Mirrahimi M; Abed Z; Beik J; Shiri I; Shiralizadeh Dezfuli A; Mahabadi VP; Kamran Kamrava S; Ghaznavi H; Shakeri-Zadeh A
Pharmacol Res; 2019 May; 143():178-185. PubMed ID: 30611856
[TBL] [Abstract][Full Text] [Related]
9. Using positron emission tomography (PET) response criteria in solid tumours (PERCIST) 1.0 for evaluation of 2'-deoxy-2'-[18F] fluoro-D-glucose-PET/CT scans to predict survival early during treatment of locally advanced non-small cell lung cancer (NSCLC).
Fledelius J; Khalil AA; Hjorthaug K; Frøkiaer J
J Med Imaging Radiat Oncol; 2016 Apr; 60(2):231-8. PubMed ID: 26678718
[TBL] [Abstract][Full Text] [Related]
10. Non-invasive Early Response Monitoring of Nanoparticle-assisted Photothermal Cancer Therapy Using
Jørgensen JT; Norregaard K; Simón Martín M; Oddershede LB; Kjaer A
Nanotheranostics; 2018; 2(3):201-210. PubMed ID: 29868345
[No Abstract] [Full Text] [Related]
11. The use of 18F-Fluoro-deoxy-glucose positron emission tomography (18F-FDG PET) as a non-invasive pharmacodynamic biomarker to determine the minimally pharmacologically active dose of AZD8835, a novel PI3Kα inhibitor.
Maynard J; Emmas SA; Ble FX; Barjat H; Lawrie E; Hancox U; Polanska UM; Pritchard A; Hudson K
PLoS One; 2017; 12(8):e0183048. PubMed ID: 28806782
[TBL] [Abstract][Full Text] [Related]
12. Initial experience in small animal tumor imaging with a clinical positron emission tomography/computed tomography scanner using 2-[F-18]fluoro-2-deoxy-D-glucose.
Tatsumi M; Nakamoto Y; Traughber B; Marshall LT; Geschwind JF; Wahl RL
Cancer Res; 2003 Oct; 63(19):6252-7. PubMed ID: 14559811
[TBL] [Abstract][Full Text] [Related]
13. In vivo imaging of therapy response to a novel pan-HER antibody mixture using FDG and FLT positron emission tomography.
Nielsen CH; Jensen MM; Kristensen LK; Dahlman A; Fröhlich C; Jacobsen HJ; Poulsen TT; Lantto J; Horak ID; Kragh M; Kjaer A
Oncotarget; 2015 Nov; 6(35):37486-99. PubMed ID: 26460961
[TBL] [Abstract][Full Text] [Related]
14. Fractionated photothermal therapy in a murine tumor model: comparison with single dose.
Simón M; Norregaard K; Jørgensen JT; Oddershede LB; Kjaer A
Int J Nanomedicine; 2019; 14():5369-5379. PubMed ID: 31409993
[No Abstract] [Full Text] [Related]
15. 3'-deoxy-3'-[18F]fluorothymidine as a new marker for monitoring tumor response to antiproliferative therapy in vivo with positron emission tomography.
Barthel H; Cleij MC; Collingridge DR; Hutchinson OC; Osman S; He Q; Luthra SK; Brady F; Price PM; Aboagye EO
Cancer Res; 2003 Jul; 63(13):3791-8. PubMed ID: 12839975
[TBL] [Abstract][Full Text] [Related]
16. Ex-vivo biodistribution and micro-PET/CT imaging of 18F-FDG, 18F-FLT, 18F-FMISO, and 18F-AlF-NOTA-PRGD2 in a prostate tumor-bearing nude mouse model.
Cheng Z; Wei R; Wu C; Qing H; Jiang X; Lu H; Chen S; Li X; Xu G; Ai H
Nucl Med Commun; 2015 Sep; 36(9):914-21. PubMed ID: 25973694
[TBL] [Abstract][Full Text] [Related]
17. Monitoring of 2-deoxy-2-[18F]fluoro-D-glucose uptake in tumor-bearing mice using high-sensitivity projection imaging: compared with PET imaging.
Liao MH; Wey SP; Jan ML; Chiang CC; Liao TZ; Chi CW; Shen LH; Jan TR
Nucl Med Commun; 2010 Dec; 31(12):1040-4. PubMed ID: 20926976
[TBL] [Abstract][Full Text] [Related]
18. Comparisons of [18F]-1-deoxy-1-fluoro-scyllo-inositol with [18F]-FDG for PET imaging of inflammation, breast and brain cancer xenografts in athymic mice.
McLarty K; Moran MD; Scollard DA; Chan C; Sabha N; Mukherjee J; Guha A; McLaurin J; Nitz M; Houle S; Wilson AA; Reilly RM; Vasdev N
Nucl Med Biol; 2011 Oct; 38(7):953-9. PubMed ID: 21982567
[TBL] [Abstract][Full Text] [Related]
19. 18F-FDG small-animal PET/CT differentiates trastuzumab-responsive from unresponsive human breast cancer xenografts in athymic mice.
McLarty K; Fasih A; Scollard DA; Done SJ; Vines DC; Green DE; Costantini DL; Reilly RM
J Nucl Med; 2009 Nov; 50(11):1848-56. PubMed ID: 19837760
[TBL] [Abstract][Full Text] [Related]
20. Can 3'-deoxy-3'-(18)F-fluorothymidine or 2'-deoxy-2'-(18)F-fluoro-d-glucose PET/CT better assess response after 3-weeks treatment by epidermal growth factor receptor kinase inhibitor, in non-small lung cancer patients? Preliminary results.
Bhoil A; Singh B; Singh N; Kashyap R; Watts A; Sarika S; Mittal BR
Hell J Nucl Med; 2014; 17(2):90-6. PubMed ID: 24997081
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
